Global Vaccine Adjuvants Market - 2023-2030
Market Overview
The global vaccine adjuvants market reached US$ 739.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,819.2 million by 2030. The global vaccine adjuvants market is expected to exhibit a CAGR of 12.2% during the forecast period (2023-2030). Market players involved in vaccine adjuvants are developing new products, which is expected to promote vaccine adjuvants market growth in the coming years.
For instance, in October 2021, Dynavax Technologies Corporation, a biopharmaceutical company, focused on developing and commercializing vaccines. The U.S. Department of Defense (DOD) announced that Dynavax had executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD's rF1V vaccine. The company commenced the Phase 2 trial in 2022.
The global vaccine adjuvants market is being driven by the growing prevalence of infectious diseases, the need for more effective vaccines, and the rising demand for vaccines due to the COVID-19 pandemic. The global vaccine adjuvants market is expected to have significant growth due to increasing demand for vaccine adjuvants in the development of new and effective vaccines.
Market Dynamics
The increasing prevalence of infectious diseases to drive global vaccine adjuvants market growth
An increase in the prevalence of infectious diseases across the globe is expected to augment the growth of the global vaccine adjuvants market during the forecast period. For instance, vaccination is one of the most efficient strategies for the prevention of infectious diseases. Tuberculosis (TB) is one of the world's deadliest infectious diseases, second only to COVID-19, and drug-resistant TB strains are still a major concern.
For instance, according to the Centers for Disease Control and Prevention report, 8,300 TB cases were observed in the U.S. in 2022. Also, the incidene of TB adherence was about 2.5 cases per 100,000 persons. Therefore, owing to these reasons, the usage of adjuvants in vaccines will increase, thereby boosting the global vaccine adjuvants market growth.
High R&D cost for adjuvant development to hamper the market growth
One of the major challenges faced by the manufacturers is the high research & development cost associated with developing a new vaccine adjuvant. Costs associated with research, development, and clinical studies are high, and the company has to recoup its investment which could have tied up capital for a decade or more.
The estimated R&D cost for a single vaccine is often based on development costs for new drugs and is in the range US$ 1–2 billion. A reason for these high costs is high failure rates (it is often cited that only 1 in every 5,000–10,000 compounds screened is approved by the FDA).
COVID-19 Impact Analysis
The COVID-19 pandemic has led to an unprecedented demand for vaccines, and adjuvants have played a critical role in enhancing the efficacy of these vaccines. For example, the Pfizer-BioNTech and Moderna COVID-19 vaccines both use adjuvants to boost the body's immune response to the vaccine. This has driven the growth of the global vaccine adjuvants market in the short term.
However, with global travel restrictions and lockdowns in place, it was difficult to transport and distribute vaccine adjuvants. This has led to shortages of certain adjuvants, which has slowed down the development and production of some vaccines. For example, Bharat Biotech Covaxin faced supply chain disruptions due to the shortage of the adjuvant, which slowed down its distribution in some countries.
Russia Ukraine Conflict Analysis
The global market for vaccine adjuvants may be affected by the ongoing conflict between Russia and Ukraine, as Russia is a major provider of aluminum hydroxide, a commonly used adjuvant in vaccines. Disruptions in the supply chains of these adjuvants due to the conflict could lead to a shortage of vaccines that depend on them.
Segment Analysis
The global vaccine adjuvants market is segmented based on product type, route of administration, disease, end user, and region.
Particulate adjuvants segment to hold the highest market share in the global vaccine adjuvants market
The particulate adjuvants segment is expected to dominate and account fo a 30.2% global vaccine adjuvant market share over the forecast period. Delivery systems (particulate adjuvants) cover materials such as lipid particles, aluminum salts (alum), and microparticles. Alum is by far the most commonly used adjuvant. This adjuvant is in the formulation of licensed vaccines against diphtheria/tetanus/pertussis (DTP), Hepatitis A (HAV), and Hepatitis B (HBV).
Thereby, the increasing prevalence of infectious diseases, the growing demand for vaccines, and the need for more effective vaccines will result in the growth of this segment over the forecast period.
Geographical Analysis
The presence of major players to dominate the North America region.
North America is expected to have a dominant global vaccine adjuvants market share of around 1/3rd of this market, as the U.S. is the largest revenue contributor in North America due to the increasing elderly population, rising prevalence of cancers, high R&D for cancer diagnostics, and development of innovative products by manufacturers in the region.
Also, the presence of major players such as, in the U.S., GlaxoSmithKline (GSK) is a leading player in the vaccine adjuvants market. The company's AS03 adjuvant has been used in several vaccines, including the H1N1 flu vaccine and the Shingrix vaccine for shingles.
Competitive Landscape
The major global players in the market include InvivoGen, OZ Biosciences, SEPPIC, SPI Pharma, Agenus, Inc, Aphios Corp, Vaxine Pty Ltd, Seqirus, Chemtrade, and Croda International.
Why Purchase the Report?
• To visualize the global vaccine adjuvants market segmentation based on product type, route of administration, diseases, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global vaccine adjuvants market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global vaccine adjuvants market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Product Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Diseases
- 3.4. Snippet by End User
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. The increasing prevalence of infectious disease to drive global vaccine adjuvant market growth during the forecast period
- 4.1.2. Restraints
- 4.1.2.1. High R&D cost for adjuvant development to hamper the market growth
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer’s Strategic Initiatives
- 6.6. Conclusion
- 7. By Product Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
- 7.2. Particulate Adjuvants
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Adjuvant Emulsions
- 7.4. Pathogen Components
- 7.5. Combination Adjuvants
- 7.6. Others
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Intramuscular*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Oral
- 8.4. Intradermal
- 8.5. Subcutaneous
- 8.6. Intranasal
- 9. By Diseases
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
- 9.1.2. Market Attractiveness Index, By Diseases
- 9.2. Infectious Disease*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Cancer
- 9.4. Others
- 10. By End User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
- 10.2. Pharmaceutical and Biotech Companies*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Research Institutes
- 10.4. Others
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. The U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. The U.K.
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 13. Company Profiles
- 13.1. InvivoGen*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. OZ Biosciences
- 13.3. SEPPIC
- 13.4. SPI Pharma
- 13.5. Agenus, Inc
- 13.6. Aphios Corp
- 13.7. Vaxine Pty Ltd
- 13.8. Seqirus
- 13.9. Chemtrade
- 13.10. Croda International
- LIST NOT EXHAUSTIVE
- 14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook